Phase II study of nedaplatin and paclitaxel for patients with previously untreated advanced squamous cell lung cancer

New treatment agents have not shown sufficient efficacy against advanced squamous cell lung cancer. In the present phase II study, the primary endpoint was the objective response rate, and the combination of nedaplatin and paclitaxel appeared safe and effective for untreated advanced squamous cell lung cancer. The objective response rate was 72.2%, and the disease control rate was 100%.